Quantcast
Channel: BioTuesdays » VTI-212
Browsing all 2 articles
Browse latest View live

Image may be NSFW.
Clik here to view.

Vital Therapies provides clinical and regulatory update

Vital Therapies (NASDAQ:VTL) has provided an update on its clinical trial programs and regulatory matters. Currently, 193 of a targeted 200 subjects have been enrolled in VTI-208, the company’s Phase 3...

View Article



Image may be NSFW.
Clik here to view.

Vital Therapies Phase 3 trial hits enrolment target

Vital Therapies (NASDAQ:VTL) has reached the 200 subject enrollment target in VTI-208, its randomized, open-label Phase 3 clinical trial in alcohol induced liver decompensation. “Executing on VTI-208...

View Article
Browsing all 2 articles
Browse latest View live




Latest Images